<DOC>
	<DOCNO>NCT00162734</DOCNO>
	<brief_summary>This Phase 3 clinical study design evaluate safety , tolerability , efficacy two dose level Infergen ( interferon alfacon-1 , CIFN ) plus Ribavirin administer daily 48 week treatment patient chronically infect hepatitis C nonresponders previous pegylated interferon alfa plus ribavirin therapy participate least 24 week treatment IRHC-001 . At time randomization IRHC-001 , treatment arm patient concurrently randomize 1:1 ration receive Interferon Alfacon-1 ( 9 15 Âµg ) + Ribavirin ( administer daily ) treatment 48 week . Patients eligible consideration receive treatment IRHC-002 complete minimum 24 week participation IRHC-001 . The protocol inform consent form use must approve Investigator 's Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) study initiate .</brief_summary>
	<brief_title>Daily-Dose Consensus Interferon Ribavirin : Efficacy Combined Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon alfacon-1</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>( Abbreviated due space constraint . ) 1 . Signed informed consent form 2 . Previously randomize NoTreatment Arm IRHC001 protocol 3 . IRHC001 notreatment patient ho either &lt; 2 log10 reduction plasma HCV RNA level bDNA assay Week 24 compare baseline detectable plasma HCV RNA bDNA TMA assay Week 48 4 . All patient potentially fertile sexual partner patient must use 2 reliable form effective contraception study &amp; 6 month cessation study drug 1 . Patients experience hepatic decompensation IRHC001 show laboratory , clinical , physiologic evidence hepatic decompensation screen IRHC002 2 . Patients , opinion Investigator Sponsor , suitable candidate enrollment would comply w/the requirement study 3 . Pregnant lactate woman 4 . Male partner woman pregnant 5 . Patients experimental protocol therapy participate IRHC001</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Liver</keyword>
	<keyword>Pegylated</keyword>
	<keyword>Interferon</keyword>
	<keyword>Alpha</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Combination</keyword>
	<keyword>Nonresponder</keyword>
	<keyword>HCV</keyword>
	<keyword>Infergen</keyword>
	<keyword>SVR</keyword>
</DOC>